These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1075 related items for PubMed ID: 19369178

  • 1. Randomized, double-blind, placebo-controlled, comparative study of human anti-TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis.
    Chen DY, Chou SJ, Hsieh TY, Chen YH, Chen HH, Hsieh CW, Lan JL.
    J Formos Med Assoc; 2009 Apr; 108(4):310-9. PubMed ID: 19369178
    [Abstract] [Full Text] [Related]

  • 2. [Adalimumab plus methotrexate for the treatment of rheumatoid arthritis: a multi-center randomized, double-blind, placebo-controlled clinical study.].
    Huang F, Zhang FC, Bao CD, Tao Y, Gu JR, Xu JH, Zhu P, Xu HJ, Zhang ZY, Zhao DB, Wu DH.
    Zhonghua Nei Ke Za Zhi; 2009 Nov; 48(11):916-21. PubMed ID: 20079321
    [Abstract] [Full Text] [Related]

  • 3. A comparative study of etanercept plus methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis: a 12-week, double-blind, randomized, placebo-controlled study.
    Lan JL, Chou SJ, Chen DY, Chen YH, Hsieh TY, Young M.
    J Formos Med Assoc; 2004 Aug; 103(8):618-23. PubMed ID: 15340661
    [Abstract] [Full Text] [Related]

  • 4. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
    Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, Teoh LS, Velagapudi RB, Noertersheuser PA, Granneman GR, Fischkoff SA, Chartash EK.
    Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493
    [Abstract] [Full Text] [Related]

  • 5. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, Fischkoff SA, Chartash EK.
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [Abstract] [Full Text] [Related]

  • 6. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.
    Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, Fischkoff SA, Chartash EK.
    Arthritis Rheum; 2004 May; 50(5):1400-11. PubMed ID: 15146409
    [Abstract] [Full Text] [Related]

  • 7. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.
    Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, Sharp J, Perez JL, Spencer-Green GT.
    Arthritis Rheum; 2006 Jan; 54(1):26-37. PubMed ID: 16385520
    [Abstract] [Full Text] [Related]

  • 8. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study.
    Kremer J, Ritchlin C, Mendelsohn A, Baker D, Kim L, Xu Z, Han J, Taylor P.
    Arthritis Rheum; 2010 Apr; 62(4):917-28. PubMed ID: 20131276
    [Abstract] [Full Text] [Related]

  • 9. The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging study.
    Weinblatt ME, Mease P, Mysler E, Takeuchi T, Drescher E, Berman A, Xing J, Zilberstein M, Banerjee S, Emery P.
    Arthritis Rheumatol; 2015 Oct; 67(10):2591-600. PubMed ID: 26138593
    [Abstract] [Full Text] [Related]

  • 10. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
    Smolen JS, Kay J, Doyle MK, Landewé R, Matteson EL, Wollenhaupt J, Gaylis N, Murphy FT, Neal JS, Zhou Y, Visvanathan S, Hsia EC, Rahman MU, GO-AFTER study investigators.
    Lancet; 2009 Jul 18; 374(9685):210-21. PubMed ID: 19560810
    [Abstract] [Full Text] [Related]

  • 11. Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study.
    Smolen JS, Kay J, Matteson EL, Landewé R, Hsia EC, Xu S, Zhou Y, Doyle MK.
    Ann Rheum Dis; 2014 Oct 18; 73(10):1811-8. PubMed ID: 23897769
    [Abstract] [Full Text] [Related]

  • 12. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.
    Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK.
    Arthritis Rheum; 2003 Jan 18; 48(1):35-45. PubMed ID: 12528101
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy.
    Li Z, Zhang F, Kay J, Fei K, Han C, Zhuang Y, Wu Z, Hsia EC.
    Int J Rheum Dis; 2016 Nov 18; 19(11):1143-1156. PubMed ID: 26259617
    [Abstract] [Full Text] [Related]

  • 14. Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens.
    Zintzaras E, Dahabreh IJ, Giannouli S, Voulgarelis M, Moutsopoulos HM.
    Clin Ther; 2008 Nov 18; 30(11):1939-55. PubMed ID: 19108784
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial.
    Greenwald MW, Shergy WJ, Kaine JL, Sweetser MT, Gilder K, Linnik MD.
    Arthritis Rheum; 2011 Mar 18; 63(3):622-32. PubMed ID: 21360491
    [Abstract] [Full Text] [Related]

  • 16. A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate.
    Genovese MC, Lee E, Satterwhite J, Veenhuizen M, Disch D, Berclaz PY, Myers S, Sides G, Benichou O.
    Ann Rheum Dis; 2013 Sep 01; 72(9):1453-60. PubMed ID: 23599435
    [Abstract] [Full Text] [Related]

  • 17. Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study.
    Strand V, Rentz AM, Cifaldi MA, Chen N, Roy S, Revicki D.
    J Rheumatol; 2012 Jan 01; 39(1):63-72. PubMed ID: 22045836
    [Abstract] [Full Text] [Related]

  • 18. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis.
    Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, Nash P, Amante EJ, Churchill M, Park W, Pons-Estel BA, Doyle MK, Visvanathan S, Xu W, Rahman MU.
    Arthritis Rheum; 2009 Aug 01; 60(8):2272-83. PubMed ID: 19644849
    [Abstract] [Full Text] [Related]

  • 19. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.
    Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF, Feldmann M.
    Arthritis Rheum; 1998 Sep 01; 41(9):1552-63. PubMed ID: 9751087
    [Abstract] [Full Text] [Related]

  • 20. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.
    Smolen JS, Han C, Bala M, Maini RN, Kalden JR, van der Heijde D, Breedveld FC, Furst DE, Lipsky PE, ATTRACT Study Group.
    Arthritis Rheum; 2005 Apr 01; 52(4):1020-30. PubMed ID: 15818697
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 54.